Sanofi chose Hanmi against threat of Lantus patent expiration
The reason why Sanofi established a technology transfer contract worth of KRW 5 trillion with Hanmi Pharm is analyzed as the company considered the patent expiration of ‘Lantus,’ its largest insulin product.
Lantus, a daily injection, is the most well-known product of Sanofi, which records KRW 9...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
